Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity

Arthur E Frankel Department of Internal Medicine, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA Until recent decades, the role of the immune system in harnessing tumor growth was based on anecdotal observations of increased cancers in immun...

Full description

Bibliographic Details
Main Author: Frankel AE
Format: Article
Language:English
Published: Dove Medical Press 2013-11-01
Series:Clinical Pharmacology : Advances and Applications
Online Access:http://www.dovepress.com/special-issue-of-clinical-pharmacology-advances-and-applications-in-ne-a15086
id doaj-68a5a334d883484ca86941e349425fd2
record_format Article
spelling doaj-68a5a334d883484ca86941e349425fd22020-11-24T22:44:00ZengDove Medical PressClinical Pharmacology : Advances and Applications1179-14382013-11-012013Supplement 113Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunityFrankel AEArthur E Frankel Department of Internal Medicine, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA Until recent decades, the role of the immune system in harnessing tumor growth was based on anecdotal observations of increased cancers in immune-compromised patients, the benefits of graft-versus-leukemia in allogeneic stem cell transplants, and the limited but reproducible anticancer activity of several lymphokines, including interferon and interleukin (IL)-2. Vaccine studies and infusions of "activated" lymphocytes yielded variable clinical responses and disease control. An improved understanding of the molecular and cell mechanisms of the innate and adaptive immune system in cancer-bearing animals and the discovery of an immune-suppressive tumor microenvironment then led to development and testing of a battery of new drug and cell-based approaches to trigger antitumor immunity. This issue of Clinical Pharmacology: Advances and Applications highlights some of the new protein-based compounds that are radically changing the cancer therapeutic landscape. The purpose of this collection of reviews is to inform the readership regarding the importance of the seismic change in cancer therapeutics and stimulate efforts to find novel niches and combinations of agents similar to recent advances in the application of cancer pathway inhibitors.http://www.dovepress.com/special-issue-of-clinical-pharmacology-advances-and-applications-in-ne-a15086
collection DOAJ
language English
format Article
sources DOAJ
author Frankel AE
spellingShingle Frankel AE
Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity
Clinical Pharmacology : Advances and Applications
author_facet Frankel AE
author_sort Frankel AE
title Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity
title_short Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity
title_full Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity
title_fullStr Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity
title_full_unstemmed Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity
title_sort special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity
publisher Dove Medical Press
series Clinical Pharmacology : Advances and Applications
issn 1179-1438
publishDate 2013-11-01
description Arthur E Frankel Department of Internal Medicine, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA Until recent decades, the role of the immune system in harnessing tumor growth was based on anecdotal observations of increased cancers in immune-compromised patients, the benefits of graft-versus-leukemia in allogeneic stem cell transplants, and the limited but reproducible anticancer activity of several lymphokines, including interferon and interleukin (IL)-2. Vaccine studies and infusions of "activated" lymphocytes yielded variable clinical responses and disease control. An improved understanding of the molecular and cell mechanisms of the innate and adaptive immune system in cancer-bearing animals and the discovery of an immune-suppressive tumor microenvironment then led to development and testing of a battery of new drug and cell-based approaches to trigger antitumor immunity. This issue of Clinical Pharmacology: Advances and Applications highlights some of the new protein-based compounds that are radically changing the cancer therapeutic landscape. The purpose of this collection of reviews is to inform the readership regarding the importance of the seismic change in cancer therapeutics and stimulate efforts to find novel niches and combinations of agents similar to recent advances in the application of cancer pathway inhibitors.
url http://www.dovepress.com/special-issue-of-clinical-pharmacology-advances-and-applications-in-ne-a15086
work_keys_str_mv AT frankelae specialissueofclinicalpharmacologyadvancesandapplicationsinnewproteintherapeuticsmodulatingtumorimmunity
_version_ 1725693477191155712